Loading clinical trials...
Loading clinical trials...
To combine oxaliplatin and taxotere in patients who have had prior cisplatin therapy in bladder cancer.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Stanford University
Collaborators
NCT06257264 · Breast Cancer, Small Cell Lung Cancer, and more
NCT07206225 · Non-muscle Invasive Bladder Cancer
NCT06770582 · Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, and more
NCT03317158 · Urothelial Carcinoma, Bladder Cancer
NCT06253871 · HER2 Mutation-Related Tumors, HER2, and more
Stanford University School of Medicine
Stanford, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions